



ASX release

21 April 2010

New pharmaceutical contract

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness non-invasively, today announced that it has signed a new US\$265,000 contract with a major international pharmaceutical company. This is an extension to an existing contract to supply SphygmoCor systems and clinical trials support services. A large portion of the contract value will be recognised in the current financial year.

During the past 120 days, AtCor has signed US\$1.53m in new pharmaceutical contracts. The company has an ongoing pipeline of new business opportunities and anticipates additional pharmaceutical contracts in the current financial year.

“This contract extension has been awarded well in advance of contract expiration,” said Duncan Ross, CEO of AtCor Medical. “The new agreement demonstrates that AtCor’s growing reputation for high levels of customer satisfaction is being recognised through expanded business with long-term clients, and reinforces AtCor’s strong market position as the leading provider of non-invasive central blood pressure measurement in clinical trials.

With the US Healthcare Reform legislation now having been signed into law, the uncertainty as to key provisions and how they may affect the pharmaceutical industry has been clarified. AtCor expects this to translate into improved deal flow from this sector.

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company’s SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in hundreds of peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au